zanubrutinib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a multi-agent combination regimen consisting of six drugs: - **Zanubrutinib** is a next-generation, highly selective Bruton tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling, leading to inhibition of malignant B-cell proliferation and survival. - **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, inducing cell death via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, resulting in apoptosis of rapidly dividing cells. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, causing DNA damage and cell death. - **Vincristine** is a vinca alkaloid that disrupts microtubule formation during mitosis, arresting cell division. - **Prednisone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties; it induces apoptosis in certain cancerous lymphoid cells. This combination brings together targeted therapy (zanubrutinib), immunotherapy (rituximab), classic cytotoxic chemotherapy agents (cyclophosphamide, doxorubicin, vincristine), and corticosteroid therapy (prednisone). Such regimens are typically used for the treatment of aggressive B-cell malignancies such as diffuse large B-cell lymphoma or mantle cell lymphoma. While combinations like R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) are standard-of-care for many lymphomas[6], the addition of zanubrutinib represents an investigational approach aiming to improve outcomes by integrating BTK inhibition with established chemo-immunotherapy backbones.

Brand names

Brukinsa + R-CHOP

Other names

zanubrutinib plus R-CHOPzanubrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone